Daclatasvir clinical trials
Also written BMS-790052, Daklinza, GS-7977 and DCV.
How each study uses daclatasvir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the daclatasvir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 24 Jul 2015 · DAKLINZA · NDA 206843 (FDA, Drugs@FDA)
- European Union
- 22 Aug 2014 · Daklinza · EMEA/H/C/003768 (EMA; now expired)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
100 studies that test it; most in 2014 (18)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 7 |
| 2010 | 4 |
| 2011 | 6 |
| 2012 | 9 |
| 2013 | 8 |
| 2014 | 18 |
| 2015 | 18 |
| 2016 | 10 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 62 · Other 38
Bristol-Myers Squibb (50) · Humanity and Health Research Centre (6) · ANRS, Emerging Infectious Diseases (3) · Tehran University of Medical Sciences (3) · Assiut University (3) · Genuine Research Center, Egypt (3) · Janssen Research & Development, LLC (2) · Tanta University (2)
Often tested with
Tested in the same studies.
Sofosbuvir (29) · Asunaprevir (25) · Ribavirin (13) · Simeprevir (11) · Beclabuvir (9) · Peginterferon lambda-1a (5) · Ledipasvir, sofosbuvir drug combination (4) · Ritonavir (4)
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test daclatasvir, phase 3 first.
- Nov 2026Treatment of CKD Patients With HCVPhase 2/3 · Tanta University
Studies
Open first, then newest update. How each study uses daclatasvir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 100
- Treatment of CKD Patients With HCVNot yet recruitingPhase 2/3Tanta UniversityNCT07770984Written as SOF+DCVHow we know
- Twelve Weeks Sofosbuvir/Daclatasvir in HCV Infected Children Aged 6-18 YearsCompletedNot applicableNational Liver Institute, EgyptNCT07905989Written as Sofosbuvir/DaclatasvirHow we know
- Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)CompletedPhase 2ANRS, Emerging Infectious DiseasesNCT02107365Written as DaclatasvirHow we know
- Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCCCompletedPhase 3National Hepatology & Tropical Medicine Research InstituteNCT02771405Written as daclatasvirHow we know
- Study of DAA Treatment for Children and Adolescents With Active HCV Infection in CambodiaActive, not recruitingNot applicableANRS, Emerging Infectious DiseasesNCT05992077Written as Sofosbuvir/DaclatasvirHow we know
- Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19CompletedPhase 2Shin Poong Pharmaceutical Co. Ltd.NCT04532931Written as Sofosbuvir/daclatasvirHow we know
- An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver DiseaseCompletedPhase 2Janssen Research & Development, LLCNCT02262728Written as DaclatasvirHow we know
- Antiviral Agents Against COVID-19 InfectionCompletedPhase 2/3Hospital do CoracaoNCT04468087Written as Daclatasvir 60 mgHow we know
- Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C InfectionCompletedPhase 4Tanta UniversityNCT02992457Written as DaclatasvirHow we know
- Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIVTerminatedPhase 3Bristol-Myers SquibbNCT01866930Written as Daclatasvir (DCV)How we know
- Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) CirrhoticsCompletedPhase 3Tehran University of Medical SciencesNCT02596880Written as DaclatasvirHow we know
- Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C VirusStatus unknownPhase 2/3Ain Shams UniversityNCT03540212Written as Daclatasvir and sofosbuvirHow we know
- Effect of New Oral Treatment for Hepatitis C Virus on Seminal ParametersCompletedPhase 2/3Benha UniversityNCT05616598Written as Sofosbuvir +daclatasvir+ simeprevir+RibavirinHow we know
- Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients SeraStatus unknownEarly Phase 1Assiut UniversityNCT03882307Written as sofosbuvir and daclatasvirHow we know
- COVID-19 Prophylaxis South Africa (COVER HCW)CompletedPhase 2University of Witwatersrand, South AfricaNCT04561063Written as Sofosbuvir/DaclatasvirHow we know
- DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)CompletedPhase 2/3Humanity and Health Research CentreNCT02555943Written as Sofosbuvir and DaclatasvirHow we know
- Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) InfectionTerminatedPhase 2Bristol-Myers SquibbNCT03487848Written as DaclatasvirHow we know
- A Drug-drug Interaction Study Between Daclatasvir and MetforminCompletedPhase 1Radboud University Medical CenterNCT02565862Written as DaclatasvirHow we know
- A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/CobicistatCompletedPhase 1Radboud University Medical CenterNCT02565888Written as DaclatasvirHow we know
- A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1CompletedPhase 3Bristol-Myers SquibbNCT02170727Written as DCV/ASV/BMS-791325How we know
See all 100 studies that test daclatasvir →
Given beside what is tested · 17 — daclatasvir is usual care or a partner of the new treatment
- Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral DrugsCompletedPhase 1ViriomNCT03706898Written as DaclatasvirHow we know
- Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]CompletedPhase 2/3Johns Hopkins Bloomberg School of Public HealthNCT03480932Written as DaclatasvirHow we know
- Safety of Sofosbuvir in People With Advanced Kidney FailureCompletedPhase 3Sanjay Gandhi Postgraduate Institute of Medical SciencesNCT03883698Written as Daclatasvir 60 mgHow we know
- Sofosbuvir in Treatment of COVID 19Status unknownPhase 2/3Tanta UniversityNCT04460443Written as DaclatasvirHow we know
- Sofosbuvir Containing Regimens in Treatment of COVID 19 PatientsStatus unknownPhase 2/3Tanta UniversityNCT04497649Written as DaclatasvirHow we know
- Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b InfectionWithdrawnPhase 2Humanity & Health Medical Group LimitedNCT03794258Written as SOF+DCV+CDI-31244How we know
- Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) InfectionCompletedPhase 2Atea Pharmaceuticals, Inc.NCT04019717Written as DaclatasvirHow we know
- SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis CStatus unknownPhase 2/3Nanjing Sanhome Pharmaceutical, Co., Ltd.NCT04070235Written as Daclatasvir dihydrochlorideHow we know
- Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir CombinationCompletedPhase 2/3Ain Shams UniversityNCT03490097Written as sofosbuvir plus daclatasvirHow we know
- Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus TrialsCompletedPhase 2Bristol-Myers SquibbNCT01428063Written as DaclatasvirHow we know
- A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3WithdrawnPhase 2Bristol-Myers SquibbNCT02551861Written as DaclatasvirHow we know
- A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis CCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT01842451Written as DaclatasvirHow we know
- Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or RibavirinTerminatedPhase 2Bristol-Myers SquibbNCT01425970Written as DaclatasvirHow we know
- UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated CirrhosisCompletedPhase 3Bristol-Myers SquibbNCT01973049Written as DaclatasvirHow we know
- Study of Drug Combination on Pharmacokinetics in Healthy VolunteersCompletedPhase 1Bristol-Myers SquibbNCT02175602Written as DCV 3DAA FDCHow we know
- To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination TabletCompletedPhase 1Bristol-Myers SquibbNCT02108639Written as DCV 3DAA FDCHow we know
- Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy SubjectsCompletedPhase 1Bristol-Myers SquibbNCT02045966Written as DCV 3DAA FDCHow we know
As the comparator · 3 — what is tested is compared with daclatasvir
- A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 InfectionCompletedPhase 3AbbVieNCT02640157Written as DaclatasvirHow we know
- A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV InfectionCompletedPhase 3Egyptian Liver HospitalNCT03186313Written as Sofosbuvir + Daclatasvir + RibavirinHow we know
- UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis CCompletedPhase 3Bristol-Myers SquibbNCT02123654Written as DaclatasvirHow we know
What changed recently
From the registry's own updates since Oct 20, 2026.
Newly registered1
- Twelve Weeks Sofosbuvir/Daclatasvir in HCV Infected Children Aged 6-18 YearsOct 30, 2026NCT07905989
Codes
What other systems call daclatasvir · ClinicalTrials.gg INT005615
- MeSH (NLM) C549273daclatasvirConfirmed NLM, Wikidata
- UNII (FDA) LI2427F9CIDACLATASVIRConfirmed FDA, NLM, Wikidata
- RxNorm 1606218Confirmed FDA, Wikidata
- Wikidata Q5207712daclatasvirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C114981DaclatasvirOne source FDA
- DrugBank DB09102One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C549273 | daclatasvir | Confirmed NLM, Wikidata |
| UNII (FDA) | LI2427F9CI | DACLATASVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1606218 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5207712 | daclatasvir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C114981 | Daclatasvir | One source FDA |
| DrugBank | DB09102 | — | One source Wikidata |
Also registered as daclatasvir hydrochloride (UNII 50ZO25C11D · RxNorm 1606217).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.